FDA rejects Alkermes depression drug

Apr 02, 2018

Alkermes announced that it received a Refusal to File letter from the U.S. FDA regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral investigational depression medicine.

The Agency has taken the position that it is unable to complete a substantive review of the NDA given insufficient evidence of overall effectiveness, and said additional clinical trials are needed before the NDA is resubmitted.

The experimental drug is being tested as an adjunctive treatment of major depressive disorder in patients with an inadequate response to standard antidepressant therapies.

Alkermes “strongly disagrees with the FDA's conclusions” and plans to appeal the FDA's decision. The drugmaker has requested a meeting with the FDA to determine appropriate next steps and what additional information may be required to resubmit the NDA.

Read the Alkermes press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments